<DOC>
	<DOCNO>NCT01957540</DOCNO>
	<brief_summary>Ticagrelor administration , whose molecule resemble adenosine , lead reduction overall mortality thrombotic cardiovascular ( CV ) event directly compare clopidogrel PLATO trial , implicate possible pleiotropic action drug . It show ticagrelor increase adenosine concentration , interfere red blood cell ' uptake inducing release ATP convert adenosine . Recent study healthy volunteer patient coronary artery disease ( CAD ) show ticagrelor increase coronary blood flow response intravenous adenosine administration . Ticagrelor administration , comparison P2Y12 inhibitor , may influence endothelial function , assess Peripheral Arterial Tonometry method ( EndoPAT 2000 system ( Itamar Medical , Caesarea , Israel ) , method evaluate endothelial dysfunction find positively correlate flow mediate dilatation ( FMD ) . This prospective , randomize study crossover design , conduct patient CAD prasugrel maintenance dose ( MD ) 10mg day least 3-month period . At Day 0 ( day randomization ) eligible patient assign either : - Ticagrelor 90mg twice day next 15 day - Prasugrel 10mg day next 15 day At Day 0 ( treatment onset ) patient wiil subject baseline peripheral arterial tonometry measurement . Measurement repeat Day 15 treatment crossover perform next 15 day ( without intervene washout period ) . At Day 30 patient subjected peripheral arterial tonometry assessment . Peripheral blood sample take patient Day 0 genotyping control .</brief_summary>
	<brief_title>Differential Effect Ticagrelor Versus Prasugrel Maintenance Dose Endothelial Function Peripheral Vessels Patients With Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Age 1874 year old 2 . Patients stable CAD submit ( ? ) percutaneous intervention Acute Coronary Syndrome receive prasugrel MD 10mg day least previous 3 month . 3 . Patients give write Informed Consent . 1 . Acute Coronary Syndrome 2 . Contraindication administration prasugrel ticagrelor 1 . Known hypersensitivity clopidogrel ticagrelor 2 . Active bleeding ( peptic ulcer , intracranial bleeding ) 3 . Severe liver impairment 4 . Any previous history intracranial bleeding transient ischemic attack ischemic cerebrovascular event 5 . Treatment potent CYP3A4 inhibitor ( ketoconazole , clarithromycin , nefazodone , ritonavir , atazanavir ) 3 . Requirement oral anticoagulant agent prior day 30 visit 4 . History gastrointestinal bleeding , genitourinary bleeding site abnormal bleeding within previous 3 month 5 . Increased risk bradyarrhythmias , accord investigator 's evaluation 6 . Severe noncontrolled chronic obstructive pulmonary disease 7 . Creatinine clearance &lt; 30ml/min/1.73mm2 8 . HbA1c &gt; 10mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ticagrelor</keyword>
	<keyword>prasugrel</keyword>
	<keyword>endothelial function</keyword>
</DOC>